<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03367572</url>
  </required_header>
  <id_info>
    <org_study_id>URCC16070</org_study_id>
    <secondary_id>NCI-2017-00902</secondary_id>
    <secondary_id>URCC16070</secondary_id>
    <secondary_id>URCC-16070</secondary_id>
    <secondary_id>R01CA200579</secondary_id>
    <secondary_id>UG1CA189961</secondary_id>
    <nct_id>NCT03367572</nct_id>
  </id_info>
  <brief_title>Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer</brief_title>
  <official_title>Treatment of Refractory Nausea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester NCORP Research Base</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and&#xD;
      dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron&#xD;
      hydrochloride and dexamethasone in improving chemotherapy-induced nausea and vomiting in&#xD;
      patients with breast cancer. Antiemetic drugs, such as prochlorperazine and olanzapine, may&#xD;
      help lessen nausea and vomiting in patients with breast cancer treated with chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine if control of nausea at cycle 2 in participants who experienced&#xD;
      chemotherapy-induced nausea and vomiting (CINV) at cycle 1 is improved by the addition of&#xD;
      either prochlorperazine or olanzapine to the control arm of netupitant, palonosetron and&#xD;
      dexamethasone.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine if olanzapine is more effective than prochlorperazine in controlling nausea&#xD;
      at cycle 2 in participants who experienced CINV at cycle 1 when used in combination with&#xD;
      netupitant, palonosetron and dexamethasone.&#xD;
&#xD;
      II. To determine if control of vomiting at cycle 2 in patients who experienced CINV at cycle&#xD;
      1 is improved by the addition of either prochlorperazine or olanzapine to the control arm of&#xD;
      netupitant, palonosetron and dexamethasone.&#xD;
&#xD;
      III. To determine if olanzapine is more effective than prochlorperazine in controlling&#xD;
      vomiting at cycle 2 in participants who experienced CINV at cycle 1 when used in combination&#xD;
      with netupitant, palonosetron and dexamethasone.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To create an empirically-based algorithm predicting nausea from breast cancer chemotherapy&#xD;
      regimens that takes into account not only state-of-the-art anti-emetic regimens but also&#xD;
      participant factors such as age, race, education, ethnicity, quality of life (QOL), alcohol&#xD;
      consumption, susceptibility to nausea, expectancy, anxiety, level of nausea on the day prior&#xD;
      to treatment, and prior history of nausea.&#xD;
&#xD;
      II. To compare the effects of the interventions on QOL, as assessed by the Functional&#xD;
      Assessment of Cancer Therapy- General (FACT-G), by following the same procedures described&#xD;
      under the primary aim and the first secondary aim, using change in the FACT-G scores as the&#xD;
      response.&#xD;
&#xD;
      III. To provide preliminary data on the frequency and severity of sleep disturbance, fatigue,&#xD;
      anxiety, and dizziness, across treatment conditions.&#xD;
&#xD;
      IV. To provide preliminary data on biological factors (e.g. glutathione [GSH] recycling,&#xD;
      genetic markers) that may help identify a subgroup of patients at high risk for development&#xD;
      of cancer-related or treatment-related side effects, or response to treatment.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      PART I: Patients receive 1 cycle of standard of care chemotherapy.&#xD;
&#xD;
      PART II: Patients with a nausea score &gt;= 3 at least once on the diary at cycle 1 chemotherapy&#xD;
      are randomized into 1 of 3 groups at cycle 2.&#xD;
&#xD;
      GROUP I: Within 1 hour prior to chemotherapy, patients receive netupitant/palonosetron&#xD;
      hydrochloride orally (PO) on day 1. Within 30 minutes prior to chemotherapy, patients also&#xD;
      receive dexamethasone PO on days 1-4. Patients also receive placebo PO with chemotherapy&#xD;
      every 8 hours (Q8H) on days 1-4.&#xD;
&#xD;
      GROUP II: Patients receive netupitant/palonosetron hydrochloride and dexamethasone as in&#xD;
      Group I. Patients also receive prochlorperazine PO Q8H and placebo PO with chemotherapy on&#xD;
      days 1-4.&#xD;
&#xD;
      GROUP III: Patients receive netupitant/palonosetron hydrochloride and dexamethasone as in&#xD;
      Group I. Patients also receive olanzapine PO and placebo PO Q8H with chemotherapy on days&#xD;
      1-4.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average nausea defined as the average nausea rating across 15 assessment points (comparing prochlorperazine or olanzapine to control arm)</measure>
    <time_frame>Up to day 4</time_frame>
    <description>Will be measured on a 7-point scale anchored by &quot;not at all nauseated&quot; and &quot;extremely nauseated&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average nausea defined as the average nausea rating across 15 assessment points (comparing olanzapine to prochlorperazine)</measure>
    <time_frame>Up to day 4</time_frame>
    <description>Will be measured on a 7-point scale anchored by &quot;not at all nauseated&quot; and &quot;extremely nauseated&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of any vomiting (yes or no)</measure>
    <time_frame>Up to day 4</time_frame>
    <description>Will assess presence of any vomiting (yes or no).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Group I (netupitant/palonosetron hydrochloride, dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within 1 hour prior to chemotherapy, patients receive netupitant/palonosetron hydrochloride PO on day 1. Within 30 minutes prior to chemotherapy, patients also receive dexamethasone PO on days 1-4. Patients also receive placebo PO with chemotherapy Q8H on days 1-4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (net/pal hydro, dexa, prochlorperazine, placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive netupitant/palonosetron hydrochloride and dexamethasone as in Group I. Patients also receive prochlorperazine PO Q8H and placebo PO with chemotherapy on days 1-4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III (net/pal hydro, dexa, olanzapine, placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive netupitant/palonosetron hydrochloride and dexamethasone as in Group I. Patients also receive olanzapine PO and placebo PO Q8H with chemotherapy on days 1-4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group I (netupitant/palonosetron hydrochloride, dexamethasone</arm_group_label>
    <arm_group_label>Group II (net/pal hydro, dexa, prochlorperazine, placebo)</arm_group_label>
    <arm_group_label>Group III (net/pal hydro, dexa, olanzapine, placebo)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>Visumetazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group I (netupitant/palonosetron hydrochloride, dexamethasone</arm_group_label>
    <arm_group_label>Group II (net/pal hydro, dexa, prochlorperazine, placebo)</arm_group_label>
    <arm_group_label>Group III (net/pal hydro, dexa, olanzapine, placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Netupitant/Palonosetron Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group I (netupitant/palonosetron hydrochloride, dexamethasone</arm_group_label>
    <arm_group_label>Group II (net/pal hydro, dexa, prochlorperazine, placebo)</arm_group_label>
    <arm_group_label>Group III (net/pal hydro, dexa, olanzapine, placebo)</arm_group_label>
    <other_name>Akynzeo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group III (net/pal hydro, dexa, olanzapine, placebo)</arm_group_label>
    <other_name>LY 170053</other_name>
    <other_name>Zydis</other_name>
    <other_name>Zyprexa</other_name>
    <other_name>Zyprexa Zydis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group I (netupitant/palonosetron hydrochloride, dexamethasone</arm_group_label>
    <arm_group_label>Group II (net/pal hydro, dexa, prochlorperazine, placebo)</arm_group_label>
    <arm_group_label>Group III (net/pal hydro, dexa, olanzapine, placebo)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prochlorperazine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group II (net/pal hydro, dexa, prochlorperazine, placebo)</arm_group_label>
    <other_name>RP 6140</other_name>
    <other_name>SKF-4657</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Group I (netupitant/palonosetron hydrochloride, dexamethasone</arm_group_label>
    <arm_group_label>Group II (net/pal hydro, dexa, prochlorperazine, placebo)</arm_group_label>
    <arm_group_label>Group III (net/pal hydro, dexa, olanzapine, placebo)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a diagnosis of breast cancer and be chemotherapy naive; NOTE: prior methotrexate&#xD;
             for non-cancerous conditions is allowed&#xD;
&#xD;
          -  Be scheduled to receive a single-day chemotherapy regimen that contains doxorubicin&#xD;
             and/or cyclophosphamide and/or carboplatin; Herceptin (trastuzumab) and other&#xD;
             chemotherapy agents will be allowed with any of these regimens&#xD;
&#xD;
          -  Be scheduled to receive an antiemetic regimen that does not contain Akynzeo; in&#xD;
             addition, the antiemetic regimen must conform with American Society of Clinical&#xD;
             Oncology (ASCO) Clinical Practice Guidelines at cycle 1&#xD;
&#xD;
          -  Be able to read English&#xD;
&#xD;
          -  Have the ability to give written informed consent&#xD;
&#xD;
          -  Have Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2&#xD;
&#xD;
          -  NOTE: patients 80 years of age or older must have approval from an oncologist or their&#xD;
             designee to participate in this study&#xD;
&#xD;
          -  NOTE: patients currently receiving warfarin must have approval from an oncologist or&#xD;
             their designee to participate in this study&#xD;
&#xD;
          -  Women of child-bearing potential must agree to use adequate contraception (hormonal or&#xD;
             barrier method of birth control, or abstinence) for the duration of the study and have&#xD;
             a negative pregnancy test within 10 days prior to the initiation of chemotherapy;&#xD;
             should a woman become pregnant or suspect she is pregnant while participating in this&#xD;
             study, she should inform her study physician immediately&#xD;
&#xD;
          -  CYCLE II PORTION ONLY: Only participants with a nausea score &gt;= 3 at least once on the&#xD;
             diary assessment from cycle 1 can be randomized for cycle 2&#xD;
&#xD;
          -  CYCLE II PORTION ONLY: Participants must be scheduled to receive the same chemotherapy&#xD;
             regimen as received at cycle 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have clinical evidence of current or impending bowel obstruction&#xD;
&#xD;
          -  Have a known history of central nervous system disease (e.g., brain metastases or a&#xD;
             seizure disorder)&#xD;
&#xD;
          -  Have dementia&#xD;
&#xD;
          -  Have uncontrolled diabetes mellitus or uncontrolled hyperglycemia&#xD;
&#xD;
          -  Have severe hepatic impairment, severe renal impairment, or end-stage renal disease as&#xD;
             determined by the treating physician&#xD;
&#xD;
          -  Have had long term treatment (&gt; 5 days within the past 30 days) with an antipsychotic&#xD;
             agent such as risperidone, quetiapine, clozapine, a phenothiazine, or a butyrophenone&#xD;
             within 30 days before enrollment or plans for such treatment during the study period;&#xD;
             NOTE: participants could have received prochlorperazine and other phenothiazines as&#xD;
             antiemetic therapy on a short term basis (i.e., =&lt; 5 days)&#xD;
&#xD;
          -  Have a known cardiac arrhythmia, uncontrolled congestive heart failure, or acute&#xD;
             myocardial infarction within the previous 6 months&#xD;
&#xD;
          -  Be taking benzodiazepines regularly (&gt; 5 days within the past 30 days); pro re nata&#xD;
             (PRN) use (=&lt; 5 days) for the short-term relief of the symptoms of anxiety, anxiety&#xD;
             associated with depressive symptoms, or as a rescue medication for breakthrough CINV&#xD;
             is allowed&#xD;
&#xD;
          -  Be taking anticholinergic medications&#xD;
&#xD;
          -  Be receiving quinolone antibiotic therapy&#xD;
&#xD;
          -  Be taking amifostine (Ethiofos)&#xD;
&#xD;
          -  Have a known hypersensitivity to olanzapine or to phenothiazines&#xD;
&#xD;
          -  CYCLE II PORTION ONLY: Must not have received Akynzeo at cycle 1&#xD;
&#xD;
          -  CYCLE II PORTION ONLY: Must still meet all the exclusion criteria for cycle 1&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luke Peppone</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester NCORP Research Base</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hawaii MU NCORP</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia McMahon</last_name>
      <phone>808-586-2979</phone>
      <email>Virginia@cc.hawaii.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>217-876-4740</phone>
      <email>rhamrick@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center NCORP</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsy Barnick</last_name>
      <phone>217-383-6963</phone>
      <email>Betsy.Barnick@carle.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gulf South MU-NCORP</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Mederos, RN</last_name>
      <phone>504-568-2428</phone>
      <email>Emede1@lsuhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Research Consortium of West Michigan</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Connie Szczepanek, RN</last_name>
      <phone>616-391-1230</phone>
      <email>connie.szczepanek@grcop.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Health Partners Inc</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle C. Janelsins</last_name>
      <phone>585-275-5513</phone>
      <email>michelle_janelsins@umc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Michelle C. Janelsins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Research Foundation NCORP</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Sartell</last_name>
      <phone>702-384-0013</phone>
      <email>k.sartell@sncrf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester NCORP Research Base</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southeast Clinical Oncology Research Program</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Burgess</last_name>
      <phone>336-777-3036</phone>
      <email>rburgess@southeastclinicaloncology.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbus NCORP</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheree Oxley</last_name>
      <phone>614-488-2745</phone>
      <email>sheree@columbuscoop.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dayton Clinical Oncology Program</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Ontko</last_name>
      <phone>937-775-1350</phone>
      <email>mary.ontko@daytonncorp.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Geisinger Cancer Institute NCORP</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Albertson</last_name>
      <phone>570-271-7854</phone>
      <email>halbertson@geisinger.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Greenville NCORP</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kin Williams</last_name>
      <phone>864-522-2066</phone>
      <email>KWilliams8@ghs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital Cancer Center Green Bay</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Koffarnus</last_name>
      <phone>715-221-6432</phone>
      <email>Amy.Koffarnus@hshs.org</email>
    </contact>
    <investigator>
      <last_name>Brian L. Burnette</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gundersen Health System</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Kettner-Sieber</last_name>
      <phone>608-775-1195</phone>
      <email>dkettne@gundersenhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aurora NCORP</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neha Glandt</last_name>
      <phone>414-778-4345</phone>
      <email>neha.glandt@aurora.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 4, 2017</study_first_submitted>
  <study_first_submitted_qc>December 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2017</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester NCORP Research Base</investigator_affiliation>
    <investigator_full_name>Luke Peppone</investigator_full_name>
    <investigator_title>Associate Professor of Surgery, Radiation Oncology, and Neuroscience</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
    <mesh_term>Prochlorperazine</mesh_term>
    <mesh_term>Ichthammol</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

